Literature DB >> 22073763

Schizophrenia: medical illness, mortality, and aging.

David A Casey1, Mercedes Rodriguez, Colleen Northcott, Garry Vickar, Lina Shihabuddin.   

Abstract

OBJECTIVE: Schizophrenia is a devastating and common psychiatric disorder which is associated with a high degree of medical morbidity and reduced life span in addition to psychosis. In this article, these problems will be discussed in the context of schizophrenia and aging.
METHOD: The recent literature was reviewed using Pubmed, Medline, and Google scholar with the search terms "schizophrenia, aging, medical problems."
RESULTS: Schizophrenia is associated with significant medical morbidity and mortality. Diabètes and cardiovascular disease, along with smoking and obesity, are over-represented and contribute to reduced quality of life and life span. Schizophrenics often receive poor medical care.
CONCLUSIONS: The impacts of schizophrenia on physical health and successful aging have been underestimated. Psychiatrists and primary care physicians need to address the overlapping medical and psychiatric aspects of the disorder while the medical care system for these patients requires a much higher degree of coordination than is currently available.

Entities:  

Mesh:

Year:  2011        PMID: 22073763     DOI: 10.2190/PM.41.3.c

Source DB:  PubMed          Journal:  Int J Psychiatry Med        ISSN: 0091-2174            Impact factor:   1.210


  17 in total

1.  Treatment response to the RENEW weight loss intervention in schizophrenia: impact of intervention setting.

Authors:  Catana Brown; Jeannine Goetz; Edna Hamera; Byron Gajewski
Journal:  Schizophr Res       Date:  2014-09-26       Impact factor: 4.939

Review 2.  Searching human brain for mechanisms of psychiatric disorders. Implications for studies on schizophrenia.

Authors:  Sabina Berretta; Stephan Heckers; Francine M Benes
Journal:  Schizophr Res       Date:  2014-11-11       Impact factor: 4.939

3.  Combination Extended Smoking Cessation Treatment Plus Home Visits for Smokers With Schizophrenia: A Randomized Controlled Trial.

Authors:  Arthur L Brody; Todd Zorick; Robert Hubert; Gerhard S Hellemann; Shabnam Balali; Sarah S Kawasaki; Lizette Y Garcia; Ryutaro Enoki; Paul Abraham; Paulina Young; Charles McCreary
Journal:  Nicotine Tob Res       Date:  2016-08-03       Impact factor: 4.244

Review 4.  Antipsychotic Drug-Induced Somnolence: Incidence, Mechanisms, and Management.

Authors:  Fang Fang; Hongwei Sun; Zuowei Wang; Ming Ren; Joseph R Calabrese; Keming Gao
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

5.  Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.

Authors:  Jonathan M Meyer; Yongcai Mao; Andrei Pikalov; Josephine Cucchiaro; Antony Loebel
Journal:  Int Clin Psychopharmacol       Date:  2015-11       Impact factor: 1.659

6.  Atypical antipsychotics in the treatment of depressive and psychotic symptoms in patients with chronic schizophrenia: a naturalistic study.

Authors:  Marco Innamorati; Stefano Baratta; Cristina Di Vittorio; David Lester; Paolo Girardi; Maurizio Pompili; Mario Amore
Journal:  Schizophr Res Treatment       Date:  2013-01-21

7.  Assessment between Dopamine Receptor D2 (DRD2) Polymorphisms and Schizophrenia in Korean Population.

Authors:  Ah Rang Cho; Sang Min Lee; Won Sub Kang; Su Kang Kim; Joo-Ho Chung
Journal:  Clin Psychopharmacol Neurosci       Date:  2012-08-31       Impact factor: 2.582

8.  Mortality and guideline-concordant care for older patients with schizophrenia: a retrospective longitudinal study.

Authors:  Jack Y Tsan; Eileen M Stock; Jazmin M Gonzalez; David S Greenawalt; John E Zeber; Emran Rouf; Laurel A Copeland
Journal:  BMC Med       Date:  2012-11-26       Impact factor: 8.775

9.  Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece.

Authors:  Thomas R Einarson; Maria Geitona; Alexandros Chaidemenos; Vasiliki Karpouza; Theodoros Mougiakos; Periklis Paterakis; Dimitrios Ploumpidis; Dionyssios Potamitis-Komis; Roman Zilbershtein; Colin Vicente; Charles Piwko; Panagiotis Kakkavas; Konstantina Paparouni; Rasmus C D Jensen; Michiel E H Hemels
Journal:  Ann Gen Psychiatry       Date:  2012-07-02       Impact factor: 3.455

10.  Improving metabolic and cardiovascular health at an early psychosis intervention program in vancouver, Canada.

Authors:  Diane H Fredrikson; Heidi N Boyda; Lurdes Tse; Zachary Whitney; Mark A Pattison; Fred J Ott; Laura Hansen; Alasdair M Barr
Journal:  Front Psychiatry       Date:  2014-09-05       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.